Result: Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2024

*Physical description scale*:

1 Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Notes*:

The oncologist. - 29, 7 (2024) , 581-588, ISSN: 1549-490X

*DOI*:

10.1093/oncolo/oyae019

*Result*: Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS